Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Key Laboratory of Nephrology, Ministry of Health and Guangdong Province, Guangzhou, China.
Blood Purif. 2018;45(1-3):95-101. doi: 10.1159/000484922. Epub 2017 Dec 12.
Sedative-hypnotic medication is widely used among continuous ambulatory peritoneal dialysis (CAPD) patients with sleep disorders; however, its effect on mortality has rarely been investigated.
Logistic regression was employed to identify factors associated with sedative-hypnotic medication, whose effect on mortality was evaluated by Cox proportional hazards models.
A total of 146 CAPD patients with sleep disorders were recruited, of which 46 patients (31.5%) used either benzodiazepines or zolpidem. Sedative-hypnotic medication was more frequently used by older patients and those with longer duration of CAPD therapy and there was no significant association between sedative-hypnotic medicines and all-cause mortality after adjusting for age, gender, diabetes, cardiovascular disease, and duration of CAPD.
Sedative-hypnotic medication was more often used by older patients and patients with a longer duration of CAPD. There was no association between these agents and all-cause mortality in CAPD patients with sleep disorders.
镇静催眠药物在患有睡眠障碍的持续性不卧床腹膜透析（CAPD）患者中广泛使用；然而，其对死亡率的影响很少被研究。
采用逻辑回归来确定与镇静催眠药物相关的因素，并用 Cox 比例风险模型评估其对死亡率的影响。
共招募了 146 名患有睡眠障碍的 CAPD 患者，其中 46 名（31.5%）患者使用苯二氮䓬类或唑吡坦。镇静催眠药物在年龄较大的患者和 CAPD 治疗时间较长的患者中更常使用，在调整年龄、性别、糖尿病、心血管疾病和 CAPD 时间后，镇静催眠药物与所有原因死亡率之间没有显著关联。
镇静催眠药物在年龄较大的患者和 CAPD 时间较长的患者中更常使用。在患有睡眠障碍的 CAPD 患者中，这些药物与全因死亡率之间没有关联。
